Next Article in Journal
Use of Antiplatelet Agents Decreases the Positive Predictive Value of Fecal Immunochemical Tests for Colorectal Cancer but Does Not Affect Their Sensitivity
Next Article in Special Issue
Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
Previous Article in Journal
Exploring the Metabolic Heterogeneity of Cancers: A Benchmark Study of Context-Specific Models
Previous Article in Special Issue
A Bioinformatics Analysis Identifies the Telomerase Inhibitor MST-312 for Treating High-STMN1-Expressing Hepatocellular Carcinoma
Article

Prognostic Factors in Primary Biliary Cholangitis: A Retrospective Study of Joint Slovak and Croatian Cohort of 249 Patients

1
2nd Department of Internal Medicine, PJ Safarik University in Kosice and L. Pasteur University Hospital, Trieda SNP 1, 040 11 Kosice, Slovakia
2
Internal Medicine Department, Hospital Poprad, a.s., 058 01 Poprad, Slovakia
3
Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Avenija Gojka Suska 6, 10000 Zagreb, Croatia
4
Department of Gastroenterology, Hepatology and Clinical Nutrition, School of Medicine, University of Zagreb, Salata ul. 2, 10000 Zagreb, Croatia
5
Department of Gastroenterology, University Hospital Merkur, Zajceva ul. 19, 10000 Zagreb, Croatia
6
5th Department of Internal Medicine, Subdivision of Gastroenterology and Hepatology, Comenius University Faculty of Medicine, University Hospital Bratislava, Ruzinovska 6, 826 06 Bratislava, Slovakia
7
Clinic of Gastroenterological Internal Medicine, Comenius University in Bratislava and University Hospital Martin, Kollarova 2, 036 59 Martin, Slovakia
8
Department of Gastroenterology, School of Medicine, University of Rijeka, Brace Branchetta 20/1, 51000 Rijeka, Croatia
*
Author to whom correspondence should be addressed.
Academic Editor: Aaron W. Bell
J. Pers. Med. 2021, 11(6), 495; https://doi.org/10.3390/jpm11060495
Received: 5 May 2021 / Revised: 26 May 2021 / Accepted: 28 May 2021 / Published: 1 June 2021
Objective: To identify pretreatment laboratory parameters associated with treatment response and to describe the relationship between treatment response and liver decompensation in patients with primary biliary cholangitis treated with ursodeoxycholic acid. Methods: We defined treatment response as both ALP ≤ 1.67 × ULN and total bilirubin ≤ 2 × ULN. Multiple logistic regression analyses were performed to adjust for confounding effects of sociodemographic variables. Results: Pretreatment total bilirubin ((TB); OR = 0.3388, 95%CI = 0.1671–0.6077), ALT (OR = 0.5306, 95%CI = 0.3830–0.7080), AST (OR = 0.4065, 95%CI = 0.2690–0.5834), ALP (OR = 0.3440, 95%CI = 0.2356–0.4723), total cholesterol ((TC); OR = 0.7730, 95%CI = 0.6242–0.9271), APRI (OR = 0.3375, 95%CI = 0.1833–0.5774), as well as pretreatment albumin (OR = 1.1612, 95%CI = 1.0706–1.2688) and ALT/ALP (OR = 2.4596, 95%CI = 1.2095–5.5472) were associated with treatment response after six months of treatment. Pretreatment TB (OR = 0.2777, 95%CI = 0.1288–0.5228), ALT (OR = 0.5968, 95%CI = 0.4354–0.7963), AST (OR = 0.4161, 95%CI = 0.2736–0.6076), ALP (OR = 0.4676, 95%CI = 0.3487–0.6048), APRI (OR = 0.2838, 95%CI = 0.1433–0.5141), as well as pretreatment albumin (OR = 1.2359, 95%CI = 1.1257–1.3714) and platelet count (OR = 1.0056, 95%CI = 1.0011–1.0103) were associated with treatment response after 12 months of treatment. Treatment response after 6 months of UDCA therapy is significantly associated with treatment response after 12 months of UDCA therapy (OR = 25.2976, 95% CI = 10.5881–68.4917). Treatment responses after 6 and 12 months of UDCA therapy decrease the risk of an episode of liver decompensation in PBC patients (OR = 12.1156, 95%CI = 3.7192–54.4826 and OR = 21.6000, 95%CI = 6.6319–97.3840, respectively). Conclusions: There are several pretreatment laboratory parameters associated with treatment response in patients with primary biliary cholangitis. Treatment response after six months is significantly associated with treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy. Treatment responses after 6 and 12 months of UDCA decrease the risk of an episode of liver decompensation. View Full-Text
Keywords: primary biliary cholangitis; ursodeoxycholic acid; prognostic factors; treatment response; liver decompensation primary biliary cholangitis; ursodeoxycholic acid; prognostic factors; treatment response; liver decompensation
Show Figures

Figure 1

MDPI and ACS Style

Gazda, J.; Drazilova, S.; Janicko, M.; Grgurevic, I.; Filipec Kanizaj, T.; Koller, T.; Bodorovska, B.; Bozin, T.; Mijic, M.; Rob, Z.; Mikolasevic, I.; Madir, A.; Kucinsky, B.; Jarcuska, P. Prognostic Factors in Primary Biliary Cholangitis: A Retrospective Study of Joint Slovak and Croatian Cohort of 249 Patients. J. Pers. Med. 2021, 11, 495. https://doi.org/10.3390/jpm11060495

AMA Style

Gazda J, Drazilova S, Janicko M, Grgurevic I, Filipec Kanizaj T, Koller T, Bodorovska B, Bozin T, Mijic M, Rob Z, Mikolasevic I, Madir A, Kucinsky B, Jarcuska P. Prognostic Factors in Primary Biliary Cholangitis: A Retrospective Study of Joint Slovak and Croatian Cohort of 249 Patients. Journal of Personalized Medicine. 2021; 11(6):495. https://doi.org/10.3390/jpm11060495

Chicago/Turabian Style

Gazda, Jakub, Sylvia Drazilova, Martin Janicko, Ivica Grgurevic, Tajana Filipec Kanizaj, Tomas Koller, Beatrica Bodorovska, Tonci Bozin, Maja Mijic, Zrinka Rob, Ivana Mikolasevic, Anita Madir, Branislav Kucinsky, and Peter Jarcuska. 2021. "Prognostic Factors in Primary Biliary Cholangitis: A Retrospective Study of Joint Slovak and Croatian Cohort of 249 Patients" Journal of Personalized Medicine 11, no. 6: 495. https://doi.org/10.3390/jpm11060495

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop